| Name | Title | Contact Details |
|---|
The Amphenol Product Overview provides a summary of the products and technologies Amphenol produces for the markets it serves. At Amphenol, technological innovation happens every day. For current, detailed information about specific Amphenol interconnect products, please contact an Amphenol business unit representative.
Aeluma develops novel optoelectronic devices for sensing and communications applications. Aeluma has pioneered a technique to manufacture devices using high performance compound semiconductor materials on large-diameter silicon wafers that are commonly used for mass market microelectronics. The technology has the potential to enhance performance and provide a path to cost-effective, large-scale manufacturing, both of which are critical for future LiDAR and other sensor applications. Aeluma is developing a streamlined business model from its headquarters in Santa Barbara, California that has a state-of-the-art manufacturing cleanroom.
nZero is a 24/7 carbon management platform that gives NGOs, government agencies and organizations the accurate emissions data they need to reach net zero and make smart decisions that benefit the health of the planet. Unlike other carbon management offerings who rely on third-party data and opaque averages, nZero gathers accurate, first-party, contextual data into a comprehensive view, making it simple for organizations to pinpoint energy opportunities within their operations, easily implement carbon reduction actions, and spend smarter along the way.
Interlocking Pavers Inc is a Saint Charles, IL-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.